Abstract
Inflammatory bowel diseases (IBD) are chronic, relapsing, and destructive inflammatory disorders of the gastrointestinal tract. Both Crohn’s disease (CD) and ulcerative colitis (UC) seem to arise from an impaired dialog between the environment and gut microbiota in genetically susceptible hosts, leading to an inappropriate immune activation and resulting in the over-production of pro-inflammatory cytokines.
IL-6 is a key modulator of inflammatory response. It is a phylogenetically important cytokine with relevance in IBD, as well as in other chronic inflammatory diseases and cancer. Influencing the production of this cytokine can change the balance of effector CD4+ T cell subsets and induce B cell antibody production. Moreover, given IL-6 is mostly produced from innate immune cells such as macrophages, neutrophils and mast cells, it is a strategic bridge between the innate and the adaptive system. Interestingly, IL-6 induced signaling can be primarily seen in a relatively small number of IL-6 responsive cells whereas in a chronic phase of inflammation it is able to activate almost all cells of the body through a process known as trans-signaling.
In this review, we discuss the role of IL-6 in chronic inflammation, with particular emphasis on its role in CD and UC, and we explore the potential to develop anti-IL-6 agents for IBD treatment.
Keywords: Biologic therapy, cytokine, Crohn’s disease, monoclonal antibody, pathogenesis, ulcerative colitis.
Current Drug Targets
Title:Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target
Volume: 14 Issue: 12
Author(s): Mariangela Allocca, Manol Jovani, Gionata Fiorino, Stefan Schreiber and Silvio Danese
Affiliation:
Keywords: Biologic therapy, cytokine, Crohn’s disease, monoclonal antibody, pathogenesis, ulcerative colitis.
Abstract: Inflammatory bowel diseases (IBD) are chronic, relapsing, and destructive inflammatory disorders of the gastrointestinal tract. Both Crohn’s disease (CD) and ulcerative colitis (UC) seem to arise from an impaired dialog between the environment and gut microbiota in genetically susceptible hosts, leading to an inappropriate immune activation and resulting in the over-production of pro-inflammatory cytokines.
IL-6 is a key modulator of inflammatory response. It is a phylogenetically important cytokine with relevance in IBD, as well as in other chronic inflammatory diseases and cancer. Influencing the production of this cytokine can change the balance of effector CD4+ T cell subsets and induce B cell antibody production. Moreover, given IL-6 is mostly produced from innate immune cells such as macrophages, neutrophils and mast cells, it is a strategic bridge between the innate and the adaptive system. Interestingly, IL-6 induced signaling can be primarily seen in a relatively small number of IL-6 responsive cells whereas in a chronic phase of inflammation it is able to activate almost all cells of the body through a process known as trans-signaling.
In this review, we discuss the role of IL-6 in chronic inflammation, with particular emphasis on its role in CD and UC, and we explore the potential to develop anti-IL-6 agents for IBD treatment.
Export Options
About this article
Cite this article as:
Allocca Mariangela, Jovani Manol, Fiorino Gionata, Schreiber Stefan and Danese Silvio, Anti-IL-6 Treatment for Inflammatory Bowel Diseases: Next Cytokine, Next Target, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113146660224
DOI https://dx.doi.org/10.2174/13894501113146660224 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Immune-Endocrine-Metabolic Unit During Human Tuberculosis
Current Immunology Reviews (Discontinued) Agonists and Antagonists Acting at P2X7 Receptor
Current Topics in Medicinal Chemistry Therapeutic Approaches for COVID-19 Based on the Interferon-Mediated Immune Responses
Current Signal Transduction Therapy IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Finding Relevant Genes Involved in the Cytotoxicity Mechanisms of Anticancer Biophores
Current Computer-Aided Drug Design Intervention of Toll-like Receptor-Mediated Human Innate Immunity and Inflammation by Synthetic Compounds and Naturally Occurring Products
Current Medicinal Chemistry Enzymes Catalyzing Protein Folding and Their Cellular Functions
Current Protein & Peptide Science Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Current Pharmaceutical Design Current Treatments of Muco-Cutaneous Herpes Simplex Virus Infections
Current Medicinal Chemistry - Anti-Infective Agents Heart Rate as a Therapeutic Target in Angina Pectoris
Current Pharmaceutical Design Involvement of Mesenchymal Stem Cells in Cancer Progression and Metastases
Current Cancer Drug Targets Transcription Factor CHF1/Hey2 Regulates Specific Pathways in Serum Stimulated Primary Cardiac Myocytes: Implications for Cardiac Hypertrophy
Current Genomics Review of Small Synthetic Molecules Targeting HBV Capsid Assembly
Medicinal Chemistry Preclinical Evaluation of a Zinc Finger Inhibitor Targeting Lentivirus Nucleocapsid Protein in SIV-Infected Monkeys
Current HIV Research Hypotensive Agents from Snake Venoms
Current Drug Targets - Cardiovascular & Hematological Disorders Involvement of Rat Hippocampal Astrocytes in β-Amyloid-Induced Angiogenesis and Neuroinflammation
Current Alzheimer Research Specific Active Immunotherapy of Cancer: Potential and Perspectives
Reviews on Recent Clinical Trials Subject Index to Volume 9
Current Pharmaceutical Design Molecular Mechanisms of Diabetic Nephropathy and Its Therapeutic Intervention
Current Drug Targets Therapeutic Approaches in Vascular Repair Induced by Adult Bone Marrow Cells and Circulating Progenitor Endothelial Cells
Current Pharmaceutical Design